News
Nasal spray may end some dental injections
-
Print -
Comments
-
“A successful trial of this new dental anesthetic will change dental technology worldwide.”
A nasal spray shown to numb the upper jaw is set to be tested in a Food and Drug Administration Phase 3 trial that will assess the spray’s effectiveness compared to the current “gold standard” treatment—painful anesthesia injections.
“A successful trial of this new dental anesthetic will change dental technology worldwide,” said Sebastian Ciancio, SUNY Distinguished Service Professor and chair of the Department of Periodontics and Endodontics in the School of Dental Medicine.
Ciancio directed the Phase 2 trial and will coordinate the Phase 3 trial. Between 6 million and 10 million dental needle injections are given daily, according to Ciancio.
Results of the FDA Phase 2 trial, conducted with 48 subjects at the UB dental school, showed that the spray appears to be safe and effective.
The Phase 3 trial will be carried out later this year at the UB dental school and other clinical sites. Ciancio said that if the Phase 3 trial is successful, it may mean the end of injections for any dental work performed on the upper teeth.
Ciancio and colleagues conducted the initial preliminary dental studies using the nasal spray, which is being developed by St. Renatus LLC, based in Fort Collins, Colo.
The nasal spray formula being tested is related to a drug used by ear, nose and throat physicians when they operate on the nose. Patients who received this anesthetic reported that their upper teeth felt numb, sparking interest in using the anesthetic for dental procedures. The spray is effective only on the upper teeth.
Other investigators involved in the Phase 2 and preliminary trials, all faculty from the School of Dental Medicine, were Eugene A. Pantera, Carol T. Pantera, Fadi Ayoub, Davis Garlapo, Nina Kim and Benita Sobierj.
Reader Comments